Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jan 20, 2022 8:20pm
146 Views
Post# 34340611

RE:RE:RE:RP2D

RE:RE:RE:RP2D

I think the more people fantasize about timing and results in a Phase 1 clinicak trial the more they are setting themselves up for major disappointment.Management does not interact in the human body ..... the drug does the work and drugs that make it all the way to Fda approval are not controlled by management once inside the body....One poster was already thinking that the dosage was so high as if they were treating elephants and not humans !!!We need to let the trial play out and hope for the best 

All that being said as one poster often writes management needs to be kept accountable for things under their control such as sales, financing, Nash partership or initiation of the Phase 3 trial and we need answers soon , very very very soon
 

Bucknelly21 wrote: Pretty disappointed....

 

 

<< Previous
Bullboard Posts
Next >>